On the eastern coast of China, along the Huangpu River, the grand event that gathers cutting-edge technologies and innovative products in the healthcare field — the 6th China International Import Expo (CIIE) — has officially opened today. As a powerhouse that has participated in every CIIE for six consecutive times, Johnson & Johnson, under the theme of "Johnson & Johnson: Renewing the Future of Health," is making its debut at the expo with a brand-new image. Showcasing over a hundred innovative products across surgical, cardiovascular, high-incidence cancers, orthopedics, eye health, immunology, mental health, infectious diseases, and rare diseases, the company is demonstrating its determination to address critical health challenges through cross-sector capabilities, as well as its commitment to being deeply rooted in China and supporting "Healthy China."
Among numerous cutting-edge products and solutions, the comprehensive ischemic stroke solution from Johnson & Johnson Medical Technologies has become a major highlight, especially the "China debut" of the new product — EMBOGUARD™ Balloon Guide Catheter — which has been a focal point at the exhibition. These groundbreaking innovative products cover the full range of stroke surgery solutions from access creation to thrombectomy, providing faster, more precise, and efficient treatment for patients with ischemic stroke, further advancing the level of stroke diagnosis and treatment in China.EMBOGUARD™ Balloon Guiding Catheter "Debuts" at CIIEFull Debut of Thrombectomy Product LineCerebrovascular disease is the leading cause of death and loss of healthy life years among residents in China, with its mortality and disability rates ranking high, imposing a heavy economic burden on many Chinese families. Among these diseases, stroke, as an acute cerebrovascular condition, poses an undeniable threat to public health. According to the "China Stroke Prevention and Treatment Report 2020," stroke is the top cause of death and disability in Chinese adults, and the number of people currently living with stroke in China ranks highest in the world.1。Stroke patients need to receive effective treatment in a short period of time, otherwise, they may die due to the rapid progression of the condition. Therefore, early prevention and treatment are of great significance in reducing the mortality rate of the disease. Clinical evidence has shown that endovascular interventional therapy can significantly improve the recanalization rate and effectively remove formed emboli.2Compared with drug treatment and surgical operation, neurointerventional technology is characterized by minimal trauma, significant efficacy, and rapid recovery. Its importance in the treatment of cerebrovascular diseases is becoming increasingly prominent.
However, during the interventional treatment process, thrombi may fragment during thrombectomy and escape to distal vessels with blood flow impact, causing new or secondary embolisms and damaging more brain cells. Therefore, at this year's CIIE, the EMBOGUARD™ Balloon Guiding Catheter has drawn significant attention from professional audiences.I learned that, as a product independently developed by Johnson & Johnson Medical Technologies, the EMBOGUARD™ Balloon Guide Catheter can temporarily block blood flow during neurointerventional thrombectomy procedures, preventing thrombus from escaping to the distal end of the blood vessel. It assists thrombectomy stents and aspiration catheters in removing intracranial thrombi, bringing good news to more patients with acute ischemic stroke.With the debut of the "new member" EMBOGUARD™ Balloon Guiding Catheter, this marks the first time Johnson & Johnson Medical Technologies has showcased its complete thrombectomy product line at the CIIE.Overall Solution for ThrombectomyPaving the Way to Life for Stroke PatientsJohnson & Johnson Medical Technology has been deeply involved in the field of neurointervention for stroke for over a decade, consistently striving to illuminate the lives of stroke patients with high-quality, innovative, and diverse products and solutions. At the exhibition booth, the author also discovered the thrombectomy comprehensive solution launched in April this year, which includes EMBOTRAP.®III Distal Closed Double-Layer Mesh Basket Thrombectomy Stent, EMBOVAC®Intracranial Thrombus Aspiration Catheter and CEREBASE®Three Cutting-Edge Products of DA Neurointervention Dedicated Long Sheath. As early as November 2022, these three products made their debut in China at the CIIE and were approved for marketing five months later, fully demonstrating the powerful spillover effect of CIIE in assisting "exhibits to become commodities."
Among them, the "star exhibit" EMBOTRAP®III is a new option for mechanical thrombectomy in acute stroke. The author learned that as a distal closed double-layer basket thrombectomy stent, EMBOTRAP III®With a unique distal closure structure, a double-layer mesh basket open-loop design, and clear stent visibility. Inside the blood vessel, it acts like a gentle "butterfly net," naturally expanding within the vessel. As it moves back, it captures thrombus in the gap between the outer frame and inner channel through a dynamic thrombus capture process, achieving rapid reperfusion of the occluded area. It can be used alone or in combination with an aspiration catheter to treat more patients with acute ischemic stroke.
EMBOVAC®It is an intracranial thrombus aspiration catheter, featuring a large lumen, durable tip, and high navigability. For patients with acute stroke, this product can help quickly remove thrombi from cerebral blood vessels, which is crucial for restoring blood flow and improving patient outcomes.
In the interventional treatment of stroke, faced with the intricate structure of cerebral blood vessels, quickly establishing a stable access is a prerequisite for the success of the surgery. To this end, CEREBASE®DA Neurointervention Dedicated Long Sheath Provides Strong Support for Neurointerventional Surgery Access. This innovative product features strong support and high placement, enabling rapid establishment of intracranial vascular access, allowing subsequent treatment devices to pass smoothly and quickly reach the lesion site, saving precious treatment time for more stroke patients with complex conditions.Empower "Healthy China," Benefit More Stroke PatientsRooted in China's healthcare industry for nearly three decades, Johnson & Johnson Medical Technology has closely aligned with the development of China's healthcare sector, always prioritizing patient needs. While accelerating the introduction of world-leading medical products, it also collaborates with the government and industry to promote the high-quality development of China's healthcare system.In the treatment of stroke, Johnson & Johnson Medical supports the "Stroke Diagnosis and Treatment Capacity Enhancement Project" initiated by the Hospital Management Research Institute of the National Health Commission. The project aims to significantly improve the overall capabilities of middle-aged and young doctors, as well as municipal and county-level medical centers, in serving stroke patients and enhancing the diagnosis and treatment abilities for acute and severe stroke cases, allowing a large number of patients to access more convenient, accessible, and high-quality medical resources. Meanwhile, the project also actively explores clinical research and evidence accumulation in stroke treatment to promote the standardization and normalization of stroke diagnosis and treatment in China, providing better protection for more stroke patients.Since entering China in 1994, Johnson & Johnson Medical Technology has been committed to advancing healthcare and tirelessly working to meet the unmet needs of Chinese patients. It is believed that in the future, Johnson & Johnson Medical Technology will continue to collaborate with industry peers, sparing no effort to make innovative and high-quality medical resources accessible to more patients and families, benefiting public welfare and jointly creating a new vision for "Healthy China."1. Summary of "China Stroke Prevention and Treatment Report 2020" [J]. Chinese Journal of Cerebrovascular Diseases, 2022, 19(2): 136-144.2. "White Paper on the Current Status and Future Development of China's Neurointervention Industry". Frost & Sullivan, 2023.3.
